A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 29 May 2018
At a glance
- Drugs Arimoclomol (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Orphazyme
- 29 May 2018 According to the Orphazyme media release, interim analysis is expected at 70% completion in H2 2020 and full analysis in H1 2021.
- 06 Apr 2018 Status changed from planning to not yet recruiting.
- 25 Oct 2017 New trial record